GH Research PLC (GHRS)vsNovartis AG ADR (NVS)
GHRS
GH Research PLC
$28.65
-1.24%
HEALTHCARE · Cap: $2.05B
NVS
Novartis AG ADR
$157.54
-1.83%
HEALTHCARE · Cap: $288.85B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
GHRS
Avoid25
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GHRS.
Margin of Safety
-71.8%
Fair Value
$93.10
Current Price
$157.54
$64.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : GHRS
The strongest argument for GHRS centers on Debt/Equity, Altman Z-Score.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : GHRS
The primary concerns for GHRS are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
GHRS carries more volatility with a beta of 1.29 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 25/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GH Research PLC
HEALTHCARE · BIOTECHNOLOGY · USA
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?